PAR

6.52%

24.5¢ paradigm biopharmaceuticals limited..

The perfect storm approaches...a drug that has been test...

First 43 Last

Share
Profile

Follow
Darksky

142 Posts.

33

27/03/21

17:26

Post #: 52086364
Share

Originally posted by Darksky: ↑

You never go broke taking a profit, I can't remember who gave me that advice but it's good,

But back to the prospect of having a substantial short position in a stock with tremendous potential IMHO.

What kind of a gap up in price might we expect if the IND for Zilusol is approved?!
I have absolutely no idea. But we are talking about a drug that has been test successfully (on evidence provided here) with over 600 SAS patients, has a long safety record in use with animals, has already caught the attention of pharmaceutical companies (again evidence here) and has a very significant market for it's use.

So, say I was running a managed fund I was short 10 million shares and had the financial capacity to run the price up and down and shake the odd loose holder out from time to time to help cover some of my position and make and book profits month by month along the way and meet my trading profit targets for managerment. What would happen if PAR receives early approval for the IND? would the share price gap up at open (remembering the FDA is in America and their announcement may occur in US time) by $2.50 to $3.00, I really don't know, but if you're short 10 million shares that's a $25 to $30 million loss. And then, what if that announcement was quickly followed by a significant deal with big pharma? Again I have absolutely no idea what that would do to the price. But what if it was an additional $5 gap up that's a potential combined loss of $75 to $80 million. Ouch!!!, and if it's an additional $10 gap up that's potentially a total loss of $125 to $130 million on the one position. Now if I was an agressive fund manager without a position in PAR and I could see the large short position and understood all the evidence about the drug, would I/they see that as an apportunity to put a short squeeze into play. I really don't know, I'm not a fund manager.But If that did occur (depending on the size of the fund) that loss could put their fund into the bottom quartile relative to their peers for quite a while. IMHO DYOR. Anyway, lets just say that a squeeze might just put a STOP to their GAME.
imho dyor

Expand

The perfect storm approaches...

a drug that has been test successfully (based on evidence provided here) with over 600 SAS patients, has a long safety record in use with animals, has already caught the attention of pharmaceutical companies (again evidence here) and has a very significant market for it's use...

AND COMPETITION HAS JUST BEEN ELIMINATED!!!

PAR Price at posting: $2.65 Sentiment: Buy Disclosure: Held
19 Upvote

0 Great analysis

Reply

Top Stories

EMD

Emyria's Empax Centre chosen for mental health clinical trial

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

FHE

Frontier Energy achieves key milestone for Waroona energy project

BRX

Belararox delineates another porphyry in Argentina at Tambo South

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

STX

Strike Energy secures $153 million for Perth Basin gas projects

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

There are more pages in this discussion • 9 more messages in this thread...

First 43 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 24.5¢		Change 0.015(6.52%)		Mkt cap ! $85.7M

Open	High	Low	Value	Volume
23.0¢	24.5¢	23.0¢	$116.0K	491.1K

Buyers (Bids)

No.	Vol.	Price($)
1	50000	23.5¢

Sellers (Offers)

Price($)	Vol.	No.
24.5¢	33682	3

View Market Depth

No.	Vol.	Price($)
1	50000	0.235
3	85622	0.230
1	100000	0.225
6	244973	0.220
4	96293	0.215

Price($)	Vol.	No.
0.245	33682	3
0.250	59284	5
0.255	21666	2
0.260	41294	6
0.265	37500	2

Last trade - 16.10pm 21/06/2024 (20 minute delay)

PAR (ASX) Chart

The perfect storm approaches...a drug that has been test...

Emyria's Empax Centre chosen for mental health clinical trial

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Frontier Energy achieves key milestone for Waroona energy project

Belararox delineates another porphyry in Argentina at Tambo South

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Strike Energy secures $153 million for Perth Basin gas projects

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The perfect storm approaches...a drug that has been test...

Top Stories

Emyria's Empax Centre chosen for mental health clinical trial

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Frontier Energy achieves key milestone for Waroona energy project

Belararox delineates another porphyry in Argentina at Tambo South

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Strike Energy secures $153 million for Perth Basin gas projects

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News